Stay updated with breaking news from Genoscience Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Genfit (OTCMKTS:GNFTF – Free Report) is one of 400 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Genfit to similar companies based on the strength of its valuation, institutional ownership, earnings, dividends, profitability, analyst recommendations and risk. Institutional and Insider Ownership 11.1% of Genfit shares are […]
The prevalence of cholangiocarcinoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cholangiocarcinoma and the
/PRNewswire/ -- 'Cholangiocarcinoma Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline cholangiocarcinoma therapies in various...
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet...
29.09.2022 - Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today ... Seite 1